bevacizumab

bevacizumab is a recombinant humanized monoclonal antibody that functions by inhibiting vascular endothelial growth factor (VEGF), a key signaling protein in angiogenesis. It was developed by Genentech and is marketed under the brand name Avastin, among others. This biopharmaceutical is primarily administered via intravenous infusion and has become a cornerstone in the treatment of several advanced malignancies.

Medical uses

Bevacizumab is approved for use in combination with standard chemotherapy for metastatic colorectal cancer, as demonstrated in pivotal trials led by researchers at the Memorial Sloan Kettering Cancer Center. It is also indicated for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer, following approvals by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency. In ophthalmology, it is used off-label to treat neovascular age-related macular degeneration and other retinal vascular diseases, though a distinct formulation, ranibizumab, was later developed specifically for ocular use.

Adverse effects

The inhibition of VEGF pathway can lead to serious adverse events, including severe hypertension and an increased risk of arterial thromboembolism, such as myocardial infarction or stroke. Gastrointestinal perforation and impaired wound healing are significant surgical risks, necessitating careful patient selection. Other notable effects include proteinuria, hemorrhage such as epistaxis, and a rare but serious risk of posterior reversible encephalopathy syndrome. These safety profiles were extensively reviewed in studies published in the New England Journal of Medicine.

Pharmacology

As a monoclonal antibody, bevacizumab binds specifically to VEGF-A, preventing its interaction with receptors VEGFR-1 and VEGFR-2 on the surface of endothelial cells. This blockade inhibits the tyrosine kinase signaling cascade critical for new blood vessel formation, thereby starving tumors of oxygen and nutrients, a concept known as antiangiogenesis. The drug has a long half-life, approximately 20 days, allowing for dosing schedules such as every two or three weeks. Its development was based on the foundational angiogenesis research of Judah Folkman at Harvard Medical School.

History

The development of bevacizumab originated from research at Genentech in the 1990s, building upon the work of Napoleone Ferrara who isolated and cloned VEGF. The first major clinical success was reported in 2003 from a trial in metastatic colorectal cancer, leading to its initial approval by the FDA in 2004. Its subsequent expansion into other cancers followed large international trials coordinated by groups like the Gynecologic Oncology Group. The drug's repurposing for ophthalmic use sparked significant debate regarding cost and regulation, highlighted in hearings before the United States Congress.

Society and culture

Bevacizumab has been at the center of major healthcare debates, particularly regarding the high cost of cancer drugs and off-label use. Its application in ophthalmology, where it is often compounded from the cancer formulation, led to a notable conflict between the FDA and the American Academy of Ophthalmology over safety regulation. The drug is listed on the World Health Organization Model List of Essential Medicines. Legal battles over patent rights involved companies like Roche and Sanofi, and its global access has been influenced by policies of organizations like NICE in the United Kingdom.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:Genentech